PT-141 (10mg)

Overview

PT-141 (Bremelanotide) is a synthetic peptide melanocortin receptor agonist developed specifically for melanocortin receptor research. Unlike other approaches that work peripherally, PT-141 acts through the central nervous system via melanocortin pathways. It's a metabolite of Melanotan II with more selective MC3R/MC4R receptor effects.

Mechanism of Action

• •Activates melanocortin receptors (MC3R and MC4R) in the central nervous system
• •Activates hypothalamic melanocortin pathways
• •Enhances dopamine and other neurotransmitter signalling
• •Works centrally rather than through vascular mechanisms
• •Affects both central and peripheral melanocortin signalling
• •Independent of testosterone levels or vascular function

Research Applications

• •Melanocortin receptor agonist research
• •HSDD-related melanocortin studies
• •Melanocortin signalling research
• •MC4R pathway investigations
• •Melanocortin signalling research
• •CNS-mediated melanocortin receptor studies

Key Research Findings

• •FDA-approved as Vyleesi (bremelanotide)
• •Research shows significant MC3R/MC4R receptor modulation
• •Studies demonstrate melanocortin signalling in research models
• •Works through unique CNS mechanism unlike PDE5 inhibitors
• •May be effective when other treatments fail

Dosage Guidelines

Research protocols typically use 0.5-2 mg administered subcutaneously, 30-60 minutes before desired effects. Effects last 4-6 hours. Not for daily use - research protocols use as-needed dosing. Reconstitute with bacteriostatic water. For research purposes only.

Storage Instructions

Store lyophilized powder at 2-8°C (refrigerated). Once reconstituted, store at 2-8°C and use within 30 days. Protect from light.